Clinical trials: Helicobacter
Helicobacter Pylori Infection
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth salts are not available.
- Trial name
- NCT02596620
- Testing
- Nexium, Amolin, Cravit
- Volunteers
- 164 people
- Sponsor
- Chang Gung Memorial Hospital
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori
- Trial name
- NCT01264822
- Testing
- Rabeprazole Sodium
- Where
- 42 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Eisai Co., Ltd.
Helicobacter Pylori Infection
Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori
The purpose of this study is to evaluate the effect of Pylera when given twice a day. Pylera approved treatment schedule is 3 pills taken 4 times daily, in addition to omeprazole given twice daily.
- Trial name
- NCT00712413
- Testing
- OBMT
- Where
- 3 sites in United States, Canada
- Sponsor
- Forest Laboratories
Helicobacter Pylori Infection
Diagnosis Ability of Linked Color Imaging for Helicobacter Pylori Infection Compared With White Light Imaging
There are lack of endoscopic criteria for diagnosing Helicobacter pylori (H. pylori) infection by conventional white light imaging (WLI).
- Trial name
- NCT03011437
- Testing
- Esophagogastroduodenoscopy
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kashgar 1st People's Hospital
Helicobacter Infection
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
At present, triple therapy are recommended by various guidelines for the treatment of Helicobacter pylori (H. pylori) infection.
- Trial name
- NCT00841854
- Testing
- pantoprazole, bismuth, metronidazole
- Where
- South Korea
- Volunteers
- 199 people
- Sponsor
- Asan Medical Center
Helicobacter Infections
Helicobacter Pylori and Proton Pump Inhibitor
The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.
- Trial name
- NCT02449941
- Testing
- PPI (proton pump inhibitor)
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Helicobacter Pylori Infection, Peptic Ulcer
Helicobacter Pylori Antibiotic Susceptibility Testing of Korea
The purpose of this study is to make nationwide registry for antimicrobial resistance of Helicobacter pylori using single method with agar dilution in Korea.
- Conditions
- Helicobacter Pylori Infection, Peptic Ulcer, Lymphoma, Gastric Cancer
- Trial name
- NCT02961296
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Asan Medical Center
Gastric Microbiota, Non-atrophic Gastritis
Difference of Gastric Microbiota in the Process of Correa's Model.
Helicobater pylori plays an important role in the development of gastric cancer. Eradication therapy can reducing the morbidity of gastric cancer, but can't totally prevent it especially when atrophy and more serious precancerous…
- Conditions
- Gastric Microbiota, Non-atrophic Gastritis, Atrophic Gastritis, Intestinal Metaplasia
- Trial name
- NCT02833363
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shandong University
Helicobacter Pylori Eradication Rate
Efficacy of Short-message-based Re-education (SMRE) on Helicobacter Pylori Eradication
Helicobacter pylori (H. pylori) is a pathogen that infects more than 50% of the human population, resulting in high healthcare costs worldwide. However, H.
- Trial name
- NCT02833623
- Testing
- Short-message-based Re-education, conventional education
- Where
- China
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Shandong University
Helicobacter Pylori, the Operative Link on Gastric Intestinal Metaplasia
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer.
- Conditions
- Helicobacter Pylori, the Operative Link on Gastric Intestinal Metaplasia, Operative Link on Gastric Intestinal Assessment
- Trial name
- NCT02933229
- Testing
- biopsy, H. pylori eradication
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shandong University
Therapeutic Duration, Helicobacter Pylori
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies. However, due to the increasing resistance rates to antibiotics, failures of H.
- Conditions
- Therapeutic Duration, Helicobacter Pylori, Antimicrobial Susceptibility Test, Eradication
- Trial name
- NCT02934048
- Testing
- 7-day triple regimen guided by AST, 10-day triple regimen guided by AST, 14-day triple regimen guided by AST
- Volunteers
- 700 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection
Primary Antimicrobial Resistance Patterns of Austrian Helicobacter Pylori Clinical Isolates
Helicobacter pylori infects ~ 50% of the world's population and a quarter of the European population. H. pylori is responsible for a large proportion of gastric and duodenal ulcers and gastritis. Chronic infection with H.
- Trial name
- NCT02925091
- Volunteers
- 2,000 people
- Sponsor
- Medical University of Vienna
Helicobacter Infection
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
As increasing the antibiotics resistance, the effectiveness of traditional Helicobacter pylori (H. pylori) therapies has been declined coincidently. In this study, the investigators evaluated the efficacy of H.
- Trial name
- NCT02349685
- Testing
- H. pylori culture and antimicrobial susceptibility test, 14 day PBMT group, 14 day MEA group
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection
Traditional Chinese Medicine Combined With Standard Triple Region for Eradication of Helicobacter Pylori
To evaluate the efficacy and safety of Traditional Chinese Medicine (TCM) decoction and powder combined with standard triple therapy on improving eradication rate of Helicobacter Pylori (H.
- Trial name
- NCT02803216
- Testing
- standard triple region, 2-week Xiang-sha-liu-jun decoction, 4-week Xiang-sha-liu-jun decoction
- Volunteers
- 576 people
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
Helicobacter Pylori Infection
Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients
The study aims to evaluate H. pylori eradication rate in diabetic patients by using novel 10-day levofloxacin-based concomitant therapy compared with conventional 10-day sequential therapy.
- Trial name
- NCT02466919
- Testing
- Pantoprazole, Amoxicillin, Metronidazole
- Volunteers
- 114 people
- Sponsor
- Chung-Tai Wu
Helicobacter Pylori Eradication
Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori
This study compared efficacy and safety of Ilaprazole based triple regimen therapy including Ilaprazole 5mg, Clarithromycin 500mg and Amoxicillin Cap(Amoxicillin) 1000mg BID on the first line eradication treatment of H.pylori
- Trial name
- NCT02873065
- Testing
- Ilaprazole, Esoprazole
- Sponsor
- Livzon Pharmaceutical Group Inc.
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Epidemiology of Helicobacter Pylori Infection Among Shanghai Children
Epidemiology of Helicobacter Pylori Infection Among Shanghai Children.
- Trial name
- NCT02160860
- Where
- China
- Volunteers
- 1,997 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Fudan University
Helicobacter Pylori Eradication Antibiotic
Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection
This study compared efficacy and safety of Ilaprazole based bismuth-containing quadruple regimen therapy including Ilaprazole 5mg, Bismuth Potassium Citrate 220mg, Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID…
- Trial name
- NCT02835560
- Testing
- Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy, Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
- Volunteers
- 100 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Gastritis, Helicobacter Pylori Associated Gastritis
New Technology to Differentiate Normal Gastric Mucosa From Helicobacter Pylori Associated Gastritis and Gastric Atrophy
Endoscopy is a tool that has greatly influenced gastroenterological diagnosis. However, conventional endoscopy is limited to detecting lesions on the basis of gross morphological changes and therefore a certainly diagnosis…
- Conditions
- Gastritis, Helicobacter Pylori Associated Gastritis, Atrophic Gastritis
- Trial name
- NCT02597517
- Testing
- Digital chromoendoscopy and magnification
- Where
- Ecuador
- Volunteers
- 72 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Helicobacter Pylori Infection
Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test
Helicobacter pylori eradication (H. pylori) rates with clarithromycin-based triple therapy are declining, and an alternative strategy is needed urgently.
- Trial name
- NCT02759029
- Testing
- eradication of Helicobacter pylori
- Where
- South Korea
- Volunteers
- 123 people
- Sponsor
- Gangnam Severance Hospital